Immunogenicity to infliximab is associated with HLA-DRB1-Reference-Cited by-同舟云学术

Immunogenicity to infliximab is associated with HLA-DRB1

Published:2015-04-15 Issue:8 Volume:64 Page:1344-1345
ISSN:0017-5749
Container-title:Gut
language:en
Short-container-title:Gut

Author:

Billiet Thomas,Vande Casteele Niels^ORCID,Van Stappen Thomas,Princen Fred,Singh Sharat,Gils Ann,Ferrante Marc,Van Assche Gert,Cleynen Isabelle,Vermeire Severine

Publisher

BMJ

Subject

Gastroenterology

Reference4 articles.

1. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab;Ungar;Gut,2014

2. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis;Buck;Arch Neurol,2011

3. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis;Goyette;Nat Genet,2015

4. Association of HLA-DRB1-restricted CD4(+) T cell responses with HIV immune control;Ranasinghe;Nat Med,2013

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive biomarkers for anti-TNF alpha therapy in IBD patients;Journal of Translational Medicine;2024-03-16

2. Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease;International Journal of Molecular Sciences;2024-02-28

3. Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis;Journal of Crohn's and Colitis;2024-01-14

4. Immunogenicity of Therapeutic Proteins;Pharmaceutical Biotechnology;2024

5. HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn’s disease;Gastroenterology Report;2023-12-22